Mandate

Vinge advises Fouriertransform in connection with investment in Norstel AB

January 27, 2010

Vinge has advised Fouriertransform, the Swedish state-owned venture capital company for the motor vehicle industry, in its acquisition of shares and convertible debentures in Norstel AB (publ). Norstel develops power supply systems and solutions and the investment amounts to EUR 10.5 million. The investment has been effected through a directed issue of new shares and convertible debentures. The investment will make Fouriertransform the company's largest individual shareholder.
 
Norstel has the potential to become one of the world's leading suppliers of Sic-wafers, which constitute an important element in the successful development and production of environmentally friendly hybrid vehicles. This is Fouriertransform's second investment. Vinge also advised on the first investment last autumn in the fuel cell company, Powercell Sweden AB.
 
Vinge's team consisted of Ulf Sallnäs, Helena Jonsson and David Andersson.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026